NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Sample GSM544738 Query DataSets for GSM544738
Status Public on May 20, 2010
Title TypeIIIGD_3
Sample type RNA
 
Source name Cultured Skin Fibroblasts, Gaucher Disease Type III
Organism Homo sapiens
Characteristics gender: male
age: 4 yrs
Treatment protocol NA
Growth protocol Cells were grown on DMEM medium (InVitrogen, Carlsbad, CA) supplemented with 20% heat-inactivated fetal bovine serum (Hyclone, Logan, UT) and 2 mM L-glutamine, and were used before passage 10. All cultures were initiated at 7.5 x 105 cells per 75 cm2 flask. The culture medium was changed every 3-4 days.
Extracted molecule total RNA
Extraction protocol On day 16, approximately 10 days post-confluence, cells were harvested following trypsinization. Cells from triplicate flasks were pooled, washed twice with phosphate buffered saline and re-suspended in PBS. Cell numbers were determined using a Coulter Counter Model Z. The total cell suspension was divided into aliquots for RNA extraction, lipid analysis, and determination of residual glucocerebrosidase activity. The cell suspensions were centrifuged at 1000 x g for 5 min and dry cell pellets were stored at -80 C until used.
Label biotin
Label protocol Labeling was performed on a sample-by-sample basis according to manufacturer’s guidelines for use with the Affymetrix Human Genome U133A_2 GeneChip (Affymetrix, Inc). DNase treatment was included as part of isolation to remove possible contaminating DNA. Bioanalyzer nanochip (Agilent, Inc) and NanoDrop (ThermoFisher, Inc) were used to validate and quantitate the RNA prior to cRNA synthesis and labeling. For cRNA synthesis and labeling, 5ug of total RNA was used per sample in conjunction with the Affymetrix 3’ one-cycle Target labeling Kit (Affymetrix, Inc).
 
Hybridization protocol Labeled cRNA were hybridized to Affymetrix Human U133A_2 GeneChips (Affymetrix, Inc) in blinded interleaved fashion.
Scan protocol Affymetrix scanner 3000 was used in conjunction with Affymetrix GeneChip Operation Software to generate ~580,000 probe measurements/hybridized cRNA.
Description Cultured Skin Fibroblasts, Gaucher Disease Type III, biological replicate 3
Data processing The “rma” function in bioconductor (http://www.bioconductor.org/) was used to summarize probe measurements and generate normalized gene fragment expression values for each hybridized cRNA. Quality of data was assured via sample-level inspection by Tukey box plot, covariance-based PCA scatter plot, and correlation-based Heat Map. Gene fragments not having at least one expression value greater then system noise were deemed non-informative and discarded. System noise was defined as the lowest expression value at which the LOWESS fit of observed CV for each gene fragment by mean expression value for each gene fragment changes from non-linear to linear. For gene fragments not discarded, expression values were floored to equal system noise if less than system noise then subject to significance testing. The one-factor ANOVA under BH FDR MCC condition (alpha criteria<0.05) was used to identify gene fragments having expression values significantly associated with differences in gender. Spearman correlation under BH FDR MCC condition (alpha criteria<0.05) was used to identify gene fragments having expression values significantly associated with differences in age. Gene fragments found to have expression values significantly associated with differences in age and/or gender were discarded before testing gene fragment expression for significant association with Type I and/or Type III GD. Testing gene fragment expression for significant association with Type I and/or Type III GD was done using the one-factor ANOVA under BH FDR MCC condition (alpha criteria<0.05). For gene fragments found to have expression significantly associated with Type I and/or Type III GD, the Tukey HSD test was used to code gene fragments having a post-hoc p-value < 0.05 between Type I GD vs. control, Type III GD vs. control, and/or Type III GD vs. Type I GD. These codes were used classify gene fragments having expression significantly association with Type I and/or Type III GD as significantly dysregulated in Type I GD only, significantly dysregulated in Type III GD only, significantly and concordantly dysregulated in both Type I GD and Type III GD, or significantly and disconcordantly dysregulated in both Type I GD and Type III GD. Gene fragment annotations and associated gene functions were obtained using IPA (Ingenuity, Inc.).
 
Submission date May 19, 2010
Last update date May 19, 2010
Contact name Kory R Johnson
E-mail(s) johnsonko@ninds.nih.gov
Phone 301-402-1956
Organization name NINDS/NIH
Department DIR IT & Bioinformatics
Lab Bioinformatics Section
Street address 10/3B01, 9000 Rockville Pike
City Bethesda
State/province MD
ZIP/Postal code 20892
Country USA
 
Platform ID GPL571
Series (1)
GSE21899 Global Gene Expression Profiles in Cultured Skin Fibroblasts Derived from Patients with Gaucher Disease

Data table header descriptions
ID_REF
VALUE log (base=2) RMA signal

Data table
ID_REF VALUE
1007_s_at 9.381542339
1053_at 6.634900161
117_at 4.360999488
121_at 8.489000446
1255_g_at 3.375198571
1294_at 7.296497916
1316_at 5.353639254
1320_at 5.950712516
1405_i_at 3.329086362
1431_at 4.640280491
1438_at 6.560178533
1487_at 7.363241202
1494_f_at 5.768280674
1598_g_at 13.14693038
160020_at 8.065333638
1729_at 8.211739462
177_at 4.966277881
1773_at 6.751156234
179_at 8.89771927
1861_at 7.58150369

Total number of rows: 22277

Table truncated, full table size 496 Kbytes.




Supplementary file Size Download File type/resource
GSM544738.CEL.gz 2.0 Mb (ftp)(http) CEL
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap